Table 3.
Survey population n = 1632 | Group A Symptomatic pharmacists n = 269 |
Group B Nonspecific Symptoms n = 355 |
Group C Asymptomatic Pharmacists n = 1008 |
Significance | |
---|---|---|---|---|---|
Business Located in a Red Area, n (%) | 576 (35,3%) | 135 (50,2%) | 127 (35,9%) | 312 (31,0%) | Group A vs, B P < 0,0003 |
Group A vs, C P < 0,00001 | |||||
Group B vs, C NS | |||||
Age, years | 40,7 (10) | 39,6 (8,9) | 39 (9,4) | 41,5 (10,4) | Group A vs, B NS |
Group A vs, C p = 0,038 | |||||
Group B vs, C p = 0,020 | |||||
Gender, Women, n (%) | 1289 (79%) | 226 (84%) | 294 (82,8%) | 776 (77%) | Group A vs, B NS |
Group A vs, C p = 0,012 | |||||
Group B vs, C p < 0,00001 | |||||
Presence of 1 Comorbidities, n (%) | 269 (16,5%) | 52 (19,3%) | 82 (23,1%) | 162 (16,1%) | Group A vs, B NS |
Group A vs, C NS | |||||
Group B vs, C p = 0,003 | |||||
Number of Pharmacy Owner, n (%) | 359 (22%) | 41 (15,2%) | 61 (17,2%) | 257 (25,5%) | Group A vs, B NS |
Group A vs, C p = 0,0004 | |||||
Group B vs, C p = 0,001 | |||||
Number of Co-workers | 4,2 (2,6) | 4,4 (2,7) | 4,2 (2,6) | 4,2 (2,6) | Group A vs, B NS |
Group A vs, C NS | |||||
Group B vs, C NS | |||||
SARS-Cov-2 Tested Colleagues, n (%) | 142 (8,7%) | 41 (15,2%) | 37 (10,4) | 64 (6,3%) | Group A vs, B NS |
Group A vs, C p < 0,00001 | |||||
Group B vs, C p < 0,00001 | |||||
SARS-Cov-2 Positive Co-Workers, n (%) | 53 (3,2%) | 23 (8,6%) | 11 (3,1%) | 19 (1,9%) | Group A vs, B p = 0,0029 |
Group A vs, C p < 0,00001 | |||||
Group B vs, C NS | |||||
SARS-Cov-2 Positive Relatives, n (%) | 33 (2,0%) | 20 (7,4%) | 5 (1,4%) | 8 (0,8%) | Group A vs, B p = 0,0001 |
Group A vs, C p < 0,00001 | |||||
Group B vs, C NS |